戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ry (eg, myoglobinuria, ischemia/reperfusion, urinary tract obstruction).
2 tigraphy (reference standard for presence of urinary tract obstruction).
3 ary ureteric bud (UB) branches can result in urinary tract obstruction.
4 , contractility, and proliferation caused by urinary tract obstruction.
5  renal adysplasia in the absence of an overt urinary tract obstruction.
6  protects itself from apoptosis triggered by urinary tract obstruction.
7 ilable on the change in kidney lipids during urinary tract obstruction.
8 diverse as sepsis, cardiorenal syndrome, and urinary tract obstruction.
9 D-ATTAC), of ischemic CKD, and of unilateral urinary tract obstruction.
10  epithelial cells in response to injury from urinary tract obstruction.
11 ree unrelated families with functional lower urinary tract obstruction and secondary CAKUT.
12 SWS in discerning no, equivocal, or definite urinary tract obstruction (area under the ROC curve rang
13 ves represent the most common cause of lower urinary tract obstruction in male infants (approximately
14                        The renal response to urinary tract obstruction is complex and involves a wide
15                                  Fetal lower urinary tract obstruction (LUTO) is associated with high
16                             Congenital lower urinary-tract obstruction (LUTO) is caused by anatomical
17 at, mouse, or pig reveal dramatic effects of urinary tract obstruction on renal growth and developmen
18 aphic evidence of no, equivocal, or definite urinary tract obstruction (P > .5) or for median SWS mea
19 on but important cause of infravesical lower urinary tract obstruction that is more common in male ur
20                                 Thus, during urinary tract obstruction, the Agtr1 on bone marrow-deri
21  Emerging evidence indicates that congenital urinary tract obstruction triggers urothelial remodellin
22                                              Urinary tract obstruction was identified in 0.4% (95% CI
23  include symptomatic stone recurrence, pain, urinary tract obstruction with acute renal impairment, i